Whats wrong with Dendreon

Quote

Anonymous

Guest
1) Zero Culture
2) Lack of Trust in Leadership
3) Fear that you will be fired for no reason
4) No consistency. People get fired so often there is no consistency in our efforts.
5) Zero transparency by leadership. JD, PA, EH and DD deploys the "shock" management style. Nobody knows what direction the organization is taking. One day everything is roses and the next day everything is upside down. And the day after that TR is gone we still dont have a VP of Sales yet.
6) Lack of Effective Leadership. Nobody has a clue where the organization is going, how to get there and who is in charge but we are all very busy scurring around to fulfill the latest whim of JD because we all live in fear of getting fired at a moments notice or put on a PIP.
 


















Anonymous said:
1) Zero Culture
2) Lack of Trust in Leadership
3) Fear that you will be fired for no reason
4) No consistency. People get fired so often there is no consistency in our efforts.
5) Zero transparency by leadership. JD, PA, EH and DD deploys the "shock" management style. Nobody knows what direction the organization is taking. One day everything is roses and the next day everything is upside down. And the day after that TR is gone we still dont have a VP of Sales yet.
6) Lack of Effective Leadership. Nobody has a clue where the organization is going, how to get there and who is in charge but we are all very busy scurring around to fulfill the latest whim of JD because we all live in fear of getting fired at a moments notice or put on a PIP.
Click to expand...

Thank you for your insight. no transparency from mgmt. so your observations are helpful
 












Anonymous said:
1) Zero Culture
2) Lack of Trust in Leadership
3) Fear that you will be fired for no reason
4) No consistency. People get fired so often there is no consistency in our efforts.
5) Zero transparency by leadership. JD, PA, EH and DD deploys the "shock" management style. Nobody knows what direction the organization is taking. One day everything is roses and the next day everything is upside down. And the day after that TR is gone we still dont have a VP of Sales yet.
6) Lack of Effective Leadership. Nobody has a clue where the organization is going, how to get there and who is in charge but we are all very busy scurring around to fulfill the latest whim of JD because we all live in fear of getting fired at a moments notice or put on a PIP.
Click to expand...

This is unfortunately true. I wish Provenge had a better home.
 












He seems to know what he is talking about. He gives details. All we hear from you (one person) is how it is a "pleasure" to be an employee. Does your opinion make everyone else's opinions wrong? For all we know, maybe you aren't an employee.
 






just listen to the company's last three quarterly conference calls to get a feel for how fast things are moving in this treatment space, some of this is Dendreon but much of it has to do with high technology product life cycles being really short
 






Anonymous said:
just listen to the company's last three quarterly conference calls to get a feel for how fast things are moving in this treatment space, some of this is Dendreon but much of it has to do with high technology product life cycles being really short
Click to expand...

Provenge is the only immunotherapy approved to treat prostate cancer. It has a unique method of action. All our competitors offer similar survival benefit. Provenge has a long life cycle ahead of it. European approval will be formally announced soon. I expect we will hear a number of positive developments outlined in our quarterly conference call next week. There is "nothing" wrong with Dendreon, just some growing pains typical of a new commercial operation. The growing pains are being systematically corrected. The future is bright for the company.
 






Anonymous said:
Provenge is the only immunotherapy approved to treat prostate cancer. It has a unique method of action. All our competitors offer similar survival benefit. Provenge has a long life cycle ahead of it. European approval will be formally announced soon. I expect we will hear a number of positive developments outlined in our quarterly conference call next week. There is "nothing" wrong with Dendreon, just some growing pains typical of a new commercial operation. The growing pains are being systematically corrected. The future is bright for the company.
Click to expand...

Hate to say it but not only has the ease of use with Zytiga and Xtandi eaten into the Provenge pool but now Xofigo has seriously started to gain momentum and providing these pts serious EOL/QOL benefits. Too bad there are no surrogate end points that can be used as ammo for the payors/physicians out there. All the others provide this.

Great product but horribly mismanaged and unfortunately will wither and die.
 






Anonymous said:
Hate to say it but not only has the ease of use with Zytiga and Xtandi eaten into the Provenge pool but now Xofigo has seriously started to gain momentum and providing these pts serious EOL/QOL benefits. Too bad there are no surrogate end points that can be used as ammo for the payors/physicians out there. All the others provide this.

Great product but horribly mismanaged and unfortunately will wither and die.
Click to expand...


I agree. Xofigo will wither and die. Doctors do not like to use radioactive based medicines.

Zytiga and Xtandi do not have "surrogate endpoints" either. In fact Zytiga failed in the pre chemo trial to show a survival benefit and has a lower NCCN treatment guideline rating than Provenge.
 






Anonymous said:
I agree. Xofigo will wither and die. Doctors do not like to use radioactive based medicines.

Zytiga and Xtandi do not have "surrogate endpoints" either. In fact Zytiga failed in the pre chemo trial to show a survival benefit and has a lower NCCN treatment guideline rating than Provenge.
Click to expand...

Also, you have two sales RDs with NO experience.
 






Anonymous said:
Hate to say it but not only has the ease of use with Zytiga and Xtandi eaten into the Provenge pool but now Xofigo has seriously started to gain momentum and providing these pts serious EOL/QOL benefits. Too bad there are no surrogate end points that can be used as ammo for the payors/physicians out there. All the others provide this.

Great product but horribly mismanaged and unfortunately will wither and die.
Click to expand...

Don't work for this company, but do read a few different boards of companies that I find interesting. Dendreon is one of them. I'm a rep at another company. Your comments sound ridiculous. A product like this doesn't just "wither and die". Also, it sounds like someone corrected you on your bold statement about surrogate end points.

Provenge has a better than solid rating by NCCN and with experience, will play a significant role in the treatment of prostate cancer. Will it be blockbuster? Not likely. But wither and die? Don't be stupid.
 






























Anonymous said:
I agree. Xofigo will wither and die. Doctors do not like to use radioactive based medicines.

Zytiga and Xtandi do not have "surrogate endpoints" either. In fact Zytiga failed in the pre chemo trial to show a survival benefit and has a lower NCCN treatment guideline rating than Provenge.
Click to expand...


This is true, there are no surrogate endpoints with either oral. You forgot to mention they dont take the manpower to prescribe and are a heck of a lot easier to give then Provenge.
 












Top Bottom
Back
Quote